Research programme - Anti-inflammatory & Metabolic disease therapeutics - Gnubiotics sciences
Latest Information Update: 27 Oct 2021
At a glance
- Originator Gnubiotics Sciences
- Class Anti-inflammatories; Glycopeptides
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 15 Oct 2021 Preclinical trials in Inflammatory bowel diseases in Switzerland (PO) (Gnubiotics pipeline, October 2021)